Developer of senotherapeutics that targets the diseases and signs of ageing. The company develops a new generation of oligonucleotide-based therapies that helps in reversing the aging of old cells and tissues through modulation of RNA splicing. This helps in the restoration of splicing factor levels and reverse senescence. The company was founded in 2020 and headquartered in Exeter, United Kingdom. It has raised $9M in series a funding, with backing from Emerging Longevity Ventures, QantX, R42 Group, Trend Investment Group, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Gene Therapy space. The company leverages advanced technology to deliver innovative solutions tailored to its target market, addressing key industry challenges and driving value for its customers.
← All startups
Senisca
Series ADeveloper of senotherapeutics that targets the diseases and signs of ageing. The company develops a new generation of oligonucleotide-based therapies that helps in reversing the aging of old cells and tissues through modulation of RNA splicing. This helps in the restoration of splicing factor levels and reverse senescence. The company was founded in 2020 and headquartered in Exeter, United Kingdom. It has raised $9M…
About
Business model
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Emerging Longevity VenturesQantXR42 GroupTrend Investment GroupAPEX VenturesLifeSpan Vision VenturesLongevitytech.fundGovTrendExeterKhaghanNotung InvestmentsTribeca Asset ManagementTivoli GroupTrend Capital Management
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ See who's investing in Life Sciences — full fund directory with check size and geography.